Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review.
🦱 탈모
🟢 메타분석/SR
메타분석
4/5 보강
TL;DR
Moderate-quality evidence suggests that daily use of oral finasteride increases hair count and improves patient and investigator assessment of hair appearance, while increasing the risk of sexual dysfunction.
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
1 patient to perceive himself as improved was 5.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
The risk of discontinuing treatment because of sexual adverse effects was similar to that of placebo (RR, 0.88 [95% CI, 0.51-1.49]; I², 5%) (moderate-quality evidence). [CONCLUSION] Moderate-quality evidence suggests that daily use of oral finasteride increases hair count and improves patient and investigator assessment of hair appearance, while increasing the risk of sexual dysfunction.
📑 코퍼스 인용 관계
· 인용됨 44
📑 인용한 논문 (6) ▾
- Herbal Remedies for Hair Loss: A Review of Efficacy and Safety. Skin appendage disorders · 2025
- Mechanisms and clinical progress of adipose-derived stem cells and their derivatives in th… Stem cell research & therapy · 2025
- Global online interest in finasteride sexual side effects. International journal of impotence research · 2024
- Comment on Current Investigations into the Postfinasteride Syndrome. International journal of trichology · 2024
- Utilising SNP Association Analysis as a Prospective Approach for Personalising Androgeneti… Dermatology and therapy · 2024
- Hair Regrowth with Novel Hemp Extract: A Case Series. International journal of trichology · 2023
연도별 인용 (2012–2026) · 합계 202
OpenAlex 토픽 ·
Hair Growth and Disorders
Ovarian function and disorders
Hops Chemistry and Applications
Abstract 🌐 Abstract
[CONTEXT] Androgenetic alopecia is the most common form of alopecia in men.
[OBJECTIVE] To determine the efficacy and safety of finasteride therapy for patients with androgenetic alopecia.
[DATA SOURCES] MEDLINE, EMBASE, CINAHL, Cochrane Registers, and LILACS were searched for randomized controlled trials reported in any language that evaluated the efficacy and safety of finasteride therapy in comparison to treatment with placebo in adults with androgenetic alopecia.
[STUDY SELECTION AND DATA EXTRACTION] Two reviewers independently evaluated eligibility and collected the data, including assessment of methodological quality (Jadad score). Outcome measures included patient self-assessment, hair count, investigator clinical assessment, global photographic assessment, and adverse effects at short term (≤12 months) and long term (≥24 months). Heterogeneity was explored by testing a priori hypotheses.
[DATA SYNTHESIS] Twelve studies fulfilled the eligibility criteria (3927 male patients), 10 of which demonstrated a Jadad score of 3 or more. The proportion of patients reporting an improvement in scalp hair was greater with finasteride therapy than with placebo treatment in the short term (relative risk [RR], 1.81 [95% confidence interval (CI), 1.42-2.32]; I², 64%) and in the long term (RR, 1.71 [95% CI, 1.15-2.53]; I², 16%); both results were considered to have moderate-quality evidence. The number needed to treat for 1 patient to perceive himself as improved was 5.6 (95% CI, 4.6-7.0) in the short term and 3.4 (95% CI, 2.6-5.1) in the long term. Moderate-quality evidence suggested that finasteride therapy increased the mean hair count from baseline in comparison to placebo treatment, expressed as a percentage of the initial count in each individual, at short term (mean difference [MD], 9.42% [95% CI, 7.95%-10.90%]; I², 50%) and at long term (MD, 24.3% [95% CI, 17.92%-30.60%]; I², 0%). Also, the proportion of patients reported as improved by investigator assessment was greater in the short term (RR, 1.80 [95% CI, 1.43-2.26]; number needed to treat, 3.7 [95% CI, 3.2-4.3]; I², 82%) (moderate-quality evidence). Moderate-quality evidence suggested an increase in erectile dysfunction (RR, 2.22 [95% CI, 1.03-4.78]; I², 1%; number needed to harm, 82.1 [95% CI, 56-231]) and a possible increase in the risk of any sexual disturbances (RR, 1.39 [95% CI, 0.99-1.95]; I², 0%). The risk of discontinuing treatment because of sexual adverse effects was similar to that of placebo (RR, 0.88 [95% CI, 0.51-1.49]; I², 5%) (moderate-quality evidence).
[CONCLUSION] Moderate-quality evidence suggests that daily use of oral finasteride increases hair count and improves patient and investigator assessment of hair appearance, while increasing the risk of sexual dysfunction.
[OBJECTIVE] To determine the efficacy and safety of finasteride therapy for patients with androgenetic alopecia.
[DATA SOURCES] MEDLINE, EMBASE, CINAHL, Cochrane Registers, and LILACS were searched for randomized controlled trials reported in any language that evaluated the efficacy and safety of finasteride therapy in comparison to treatment with placebo in adults with androgenetic alopecia.
[STUDY SELECTION AND DATA EXTRACTION] Two reviewers independently evaluated eligibility and collected the data, including assessment of methodological quality (Jadad score). Outcome measures included patient self-assessment, hair count, investigator clinical assessment, global photographic assessment, and adverse effects at short term (≤12 months) and long term (≥24 months). Heterogeneity was explored by testing a priori hypotheses.
[DATA SYNTHESIS] Twelve studies fulfilled the eligibility criteria (3927 male patients), 10 of which demonstrated a Jadad score of 3 or more. The proportion of patients reporting an improvement in scalp hair was greater with finasteride therapy than with placebo treatment in the short term (relative risk [RR], 1.81 [95% confidence interval (CI), 1.42-2.32]; I², 64%) and in the long term (RR, 1.71 [95% CI, 1.15-2.53]; I², 16%); both results were considered to have moderate-quality evidence. The number needed to treat for 1 patient to perceive himself as improved was 5.6 (95% CI, 4.6-7.0) in the short term and 3.4 (95% CI, 2.6-5.1) in the long term. Moderate-quality evidence suggested that finasteride therapy increased the mean hair count from baseline in comparison to placebo treatment, expressed as a percentage of the initial count in each individual, at short term (mean difference [MD], 9.42% [95% CI, 7.95%-10.90%]; I², 50%) and at long term (MD, 24.3% [95% CI, 17.92%-30.60%]; I², 0%). Also, the proportion of patients reported as improved by investigator assessment was greater in the short term (RR, 1.80 [95% CI, 1.43-2.26]; number needed to treat, 3.7 [95% CI, 3.2-4.3]; I², 82%) (moderate-quality evidence). Moderate-quality evidence suggested an increase in erectile dysfunction (RR, 2.22 [95% CI, 1.03-4.78]; I², 1%; number needed to harm, 82.1 [95% CI, 56-231]) and a possible increase in the risk of any sexual disturbances (RR, 1.39 [95% CI, 0.99-1.95]; I², 0%). The risk of discontinuing treatment because of sexual adverse effects was similar to that of placebo (RR, 0.88 [95% CI, 0.51-1.49]; I², 5%) (moderate-quality evidence).
[CONCLUSION] Moderate-quality evidence suggests that daily use of oral finasteride increases hair count and improves patient and investigator assessment of hair appearance, while increasing the risk of sexual dysfunction.
- 95% CI 1.15-2.53
Moderate-quality evidence suggests that daily use of oral finasteride increases hair count and improves patient and investigator assessment of hair appearance, while increasing the risk of sexual dysf
APA 7
Mella, J. M., Perret, M. C., Manzotti, M., Catalano, H. N., & Guyatt, G. (2010). Efficacy and safety of finasteride therapy for androgenetic alopecia: A systematic review.. Archives of dermatology, 146(10), 1141-50. https://doi.org/10.1001/archdermatol.2010.256
Vancouver
Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Archives of dermatology. 2010;146(10):1141-50. doi:10.1001/archdermatol.2010.256
AMA 11
Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Archives of dermatology. 2010;146(10):1141-50. doi:10.1001/archdermatol.2010.256
Chicago
Mella, J. M., Perret, M. C., Manzotti, M., Catalano, H. N., and Guyatt, G.. 2010. "Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review." Archives of dermatology 146 (10): 1141-50. https://doi.org/10.1001/archdermatol.2010.256
MLA 9
Mella, J. M., et al. "Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review." Archives of dermatology, vol. 146, no. 10, 2010, pp. 1141-50. doi:10.1001/archdermatol.2010.256.
PMID
20956649 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
인용 관계
그래프 OA 노드: 6/8 (75%)
· 참조 0편 · 후속 6편
이 논문을 인용한 후속 연구 20
- Androgenetic Alopecia: An Update of Treatment Options.
- A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot st…
- Complementary and Alternative Treatments for Alopecia: A Comprehensive Review.
- Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs.
- The Diagnosis and Treatment of Hair and Scalp Diseases.
- Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?
- Hair Regeneration Therapy: Application of Adipose-Derived Stem Cells.
- Red ginseng extract promotes the hair growth in cultured human hair follicles.
- Finasteride and sexual side effects.
- Response to Microneedling Treatment in Men with Androgenetic Alopecia Who Failed to Respond to Conve…
- Immunohistochemical evaluation of androgen receptor and nerve structure density in human prepuce fro…
- Hair loss and regeneration performed on animal models.
- Advancing Regenerative Cellular Therapies in Non-Scarring Alopecia.
- Advances in hair growth.
- Comparative effectiveness of low-level laser therapy for adult androgenic alopecia: a system review …
- Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutas…
- Development of finasteride polymer microspheres for systemic application in androgenic alopecia.
- Association between Androgenetic Alopecia and Psychosocial Disease Burden: A Cross-Sectional Survey …
- Progressive expression of PPARGC1α is associated with hair miniaturization in androgenetic alopecia.
- Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine t…
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- 피나스테리드가 전립선암 발생에 미치는 영향.
- COVID-19의 50가지 이상의 장기 후유증: 체계적 문헌고찰 및 메타분석.
- 양성 전립선 비대증의 임상적 진행에 대한 doxazosin, finasteride 및 병용 요법의 장기 효과.
- 양성 전립선 비대증 환자에서 finasteride의 효과. The Finasteride Study Group.
- 양성 전립선 비대증 남성에서 급성 요폐의 위험과 수술적 치료 필요성에 대한 finasteride의 효과. Finasteride Long-Term Efficacy and Safety Study Group.
- 원형 탈모.